Advocating recombinant human erythropoietin as standard practice in Europe for treatment of cancer-related anaemia.
Coiffier
B
B
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D000970:Antineoplastic Agents / Q000009:adverse effects; D004921:Erythropoietin / Q000592:standards / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010344:Patient Advocacy / Q000191:economics / Q000592:standards; D017410:Practice Guidelines as Topic / Q000592:standards*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D004921:Erythropoietin